Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: Effects of omega-3 polyunsaturated fatty acid supplementation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 91, Issue 5, 2014, Pages 183-193

  Signorini, Cinzia ^a   De Felice, Claudio ^b   Leoncini, Silvia ^a,b   Durand, Thierry ^c   Galano, Jean Marie ^c   Cortelazzo, Alessio ^a,b   Zollo, Gloria ^a,b   Guerranti, Roberto ^a   Gonnelli, Stefano ^d   Caffarelli, Carla ^d   Rossi, Marcello ^b   Pecorelli, Alessandra ^a,b   Valacchi, Giuseppe ^e   Ciccoli, Lucia ^a   Hayek, Joussef ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c CNRS   (France)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

Erythrocyte membrane; Inflammation; Isoprostanes; Omega 3 polyunsaturated fatty acids; Rett syndrome

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID; FISH OIL; ICOSAPENTAENOIC ACID; LIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SATURATED FATTY ACID; TRANS FATTY ACID; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LIPID BLOOD LEVEL; LIPID PEROXIDATION; OXIDATION REDUCTION STATE; RANDOMIZED CONTROLLED TRIAL; RETT SYNDROME; ANIMAL; BLOOD; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANIMALS; BIOMARKERS; CHILD; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTE MEMBRANE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFLAMMATION; ISOPROSTANES; LIPIDS; RETT SYNDROME;

EID: 84908137343     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.08.002     Document Type: Article

References (96)

1. Zeman M., Jirak R., Vecka M., Raboch J., Zak A. N-3 polyunsaturated fatty acids in psychiatric diseases: mechanisms and clinical data. Neuroendocrinol. Lett. 2012, 33:736-748.
2. Schuchardt J.P., Huss M., Stauss-Grabo M., Hahn A. Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur. J. Pediatr. 2010, 169:149-164.
3. Prior P.L., Galduróz J.C. (N-3) fatty acids: molecular role and clinical uses in psychiatric disorders. Adv. Nutr. 2012, 3:257-265.
4. Simopoulos A.P. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol. Neurobiol. 2011, 44:203-215.
5. Cederholm T., Salem N., Palmblad J. ω-3 Fatty acids in the prevention of cognitive decline in humans. Adv. Nutr. 2013, 4:672-676.
6. Haast R.A., Kiliaan A.J. Impact of fatty acids on brain circulation, structure and function. Prostaglandins Leukot. Essent. Fatty Acids 2014, 10.1016/j.plefa.2014.01.002.
7. Mori T.A. Dietary n-3 PUFA and CVD: a review of the evidence. Proc. Nutr. Soc. 2014, 73:57-64.
8. Giordano E., Visioli F. Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. Prostaglandins Leukot. Essent. Fatty Acids 2014, 90:1-4.
9. Rett A. Uber ein eigartiges hirnatrophisches Syndrom bei Hyperammoniamie in Kindesalter. Wien Med. Wochenschr. 1966, 116:723-738.
10. Chahrour M., Jung S.Y., Shaw C., et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
11. Jones P.L., Veenstra G.J., Wade P.A., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998, 19:187-191.
12. Bienvenu T., Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat. Rev. Genet. 2006, 7:415-426.
13. Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8:61-65.
14. Neul J.L., Kaufmann W.E., Glaze D.G., et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 2010, 68:944-950.
15. De Felice C., Signorini C., Leoncini S., et al. The role of oxidative stress in Rett syndrome: an overview. Ann. N. Y. Acad. Sci. 2012, 1259:121-135.
16. Blardi P., de Lalla A., D'Ambrogio T., et al. Rett syndrome and plasma leptin levels. J. Pediatr. 2007, 150:37-39.
17. Grillo E., Lo Rizzo C., Bianciardi L., et al. Revealing the complexity of a monogenic disease: Rett syndrome exome sequencing. PLoS One 2013, 8:e56599.
18. Sticozzi C., Belmonte G., Pecorelli A., et al. Scavenger receptor B1 post-translational modifications in Rett syndrome. FEBS Lett. 2013, 587:2199-2204.
19. Nagy G., Ackerman S.L. Cholesterol metabolism and Rett syndrome pathogenesis. Nat. Genet. 2013, 45:965-967.
20. Janc O.A., Müller M. The free radical scavenger Trolox dampens neuronal hyperexcitability, reinstates synaptic plasticity, and improves hypoxia tolerance in a mouse model of Rett syndrome. Front. Cell. Neurosci. 2014, 8:56.
21. Gold W.A., Williamson S.L., Kaur S., et al. Mitochondrial dysfunction in the skeletal muscle of a mouse model of Rett syndrome (RTT): implications for the disease phenotype. Mitochondrion 2014, 15C:10-17.
22. De Felice C., Della Ragione F., Signorini C., et al. Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome. Neurobiol. Dis. 2014, 68:66-77.
23. De Felice C., Signorini C., Durand T., et al. Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. Genes Nutr. 2012, 7:447-458.
24. Leoncini S., De Felice C., Signorini C., et al. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep. 2011, 16:145-153.
25. Signorini C., De Felice C., Leoncini S., et al. F4-neuroprostanes mediate neurological severity in Rett syndrome. Clin. Chim. Acta 2011, 412:1399-1406.
26. Ciccoli L., De Felice C., Paccagnini E., et al. Morphological changes and oxidative damage in Rett syndrome erythrocytes. Biochim. Biophys. Acta 2012, 1820:511-520.
27. De Felice C., Signorini C., Leoncini S., et al. Fatty acids and autism spectrum disorders: the Rett syndrome conundrum. Food Nutr. Sci. 2013, 4:71-75.
28. De Felice C., Cortelazzo A., Signorini C., et al. Effects of ω-3 polyunsaturated fatty acids on plasma proteome in Rett syndrome. Mediat. Inflamm. 2013, 2013:723269.
29. Tarquinio D.C., Motil K.J., Hou W., et al. Growth failure and outcome in Rett syndrome: specific growth references. Neurology 2012, 79:1653-1661.
30. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 226:497-509.
31. Ghezzo A., Visconti P., Abruzzo P.M., et al. Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features. PLoS One 2013, 8:e66418.
32. Galano J.M., Mas E., Barden A., et al. Isoprostanes and neuroprostanes: total synthesis, biological activity and biomarkers of oxidative stress in humans. Prostaglandins Other Lipid Mediat. 2013, 107:95-102.
33. Signorini C., De Felice C., Durand T., et al. Isoprostanes and 4-hydroxy-2-nonenal: markers or mediators of disease? Focus on Rett syndrome as a model of autism spectrum disorder. Oxid. Med. Cell. Longev. 2013, 2013:343824.
34. Milne G.L., Yin H., Hardy K.D., Davies S.S., Roberts L.J. Isoprostane generation and function. Chem. Rev. 2011, 111:5973-5996.
35. Signorini C., Comporti M., Giorgi G. Ion trap tandem mass spectrometric determination of F2-isoprostanes. J. Mass Spectrom. 2003, 38:1067-1074.
36. H. Greiling, A.M. Gressner, Lehrbuch der Klinischen Chemie und Pathobiochemie, third ed., Stuttgart/New York, Schattauer, 1995.
37. Harris N., Galpchian V., Rifai N. Three routine methods for measuring high-density lipoprotein cholesterol compared with the reference method. Clin. Chem. 1996, 42:738-743.
38. Kaplan L.A., Pesce A.J. Clinical Chemistry, Theory, Analysis and Correlation 1996, Mosby St. Louis, Mosby-Year Book Inc. third ed.
39. Tietz N.W. Clinical Guide to Laboratory Tests 1995, 610-611. WB Saunders Company, Philadelphia. third ed.
40. Müller-Eberhard H.J. Complement: chemistry and pathways. Inflammation: Basic Principles and Clinical Correlates 1988, 21-53. Raven Press, New York. I. Gallin, I.M. Goldstein, R. Snyderman (Eds.).
41. Wagner C., Dati F. Fibrinogen. Clinical Laboratory Diagnostics 1998, 609-612. TH-Book Verlagsgeselisshaft, Frankfurt. L. Thomas (Ed.).
42. Piva E., Pajola R., Temporin V., et al. A new turbidimetric standard to improve the quality assurance of the erythrocyte sedimentation rate measurement. Clin. Biochem. 2007, 40:491-495.
43. Hill V.L., Simpson V.Z., Higgins J.M., et al. Evaluation of the performance of the Sysmex XT-2000i hematology analyzer with whole bloods stored at room temperature. Lab. Med. 2009, 40:709-718.
44. Gonnelli S., Caffarelli C., Hayek J., et al. Bone ultrasonography at phalanxes in patients with Rett syndrome: a 3-year longitudinal study. Bone 2008, 42:737-742.
45. Fowler V.M. The human erythrocyte plasma membrane: a Rosetta Stone for decoding membrane-cytoskeleton structure. Curr. Top. Membr. 2013, 72:39-88.
46. Kim M., Nam J.H., Oh D.H., Park Y. Erythrocyte α-linolenic acid is associated with the risk for mild dementia in Korean elderly. Nutr. Res. 2010, 30:756-761.
47. Tan Z.S., Harris W.S., Beiser A.S., et al. Red blood cell ω3 fatty acid levels and markers of accelerated brain aging. Neurology 2012, 78:658-664.
48. Ferreri C., Chatgilialoglu C. Role of fatty acid-based functional lipidomics in the development of molecular diagnostic tools. Exp. Rev. Mol. Diagn. 2012, 12:767-780.
49. Highlights of Changes from DSM-IV-TR to DSM-5, American Psychiatric Publishing, pp. 1-19.
50. Percy A.K. Rett syndrome: exploring the autism link. Arch. Neurol. 2011, 68:985-989.
51. Fu L., Huang M., Chen S. Primary carnitine deficiency and cardiomyopathy. Korean Circ. J. 2013, 43:785-792.
52. Cardoso H.D., Santos E.F., de Santana D.F., et al. Omega-3 deficiency and neurodegeneration in the substantia nigra: involvement of increased nitric oxide production and reduced BDNF expression. Biochim. Biophys. Acta 2013, 1840:1902-1912.
53. Fujii M., Nakashima H., Tomozawa J., et al. Deficiency of n-6 polyunsaturated fatty acids is mainly responsible for atopic dermatitis-like pruritic skin inflammation in special diet-fed hairless mice. Exp. Dermatol. 2013, 22:272-277.
54. Innis S.M., Novak E.M., Keller B.O. Long chain omega-3 fatty acids: micronutrients in disguise. Prostaglandins Leukot. Essent. Fatty Acids 2013, 88:91-95.
55. Motil K.J., Caeg E., Barrish J.O., et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 2012, 55:292-298.
56. Baikie G., Ravikumara M., Downs J., et al. Gastrointestinal dysmotility in Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 2014, 58:244-251.
57. Isaacs J.S., Murdock M., Lane J., Percy A.K. Eating difficulties in girls with Rett syndrome compared with other developmental disabilities. J. Am. Diet. Assoc. 2003, 103:224-230.
58. Williams K., Marraffa C. No evidence yet to support omega-3 fatty acids as a treatment for autism. J. Paediatr. Child Health 2012, 48:534-536.
59. Tan M.L., Ho J.J., Teh K.H. Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders. Cochrane Database Syst. Rev. 2012, 12:CD009398.
60. Lyall K., Munger K.L., O'Reilly É.J., Santangelo S.L., Ascherio A. Maternal dietary fat intake in association with autism spectrum disorders. Am. J. Epidemiol. 2013, 178:209-220.
61. Yin H., Liu W., Goleniewska K., Porter N.A., Morrow J.D., Peebles R.S. Dietary supplementation of omega-3 fatty acid-containing fish oil suppresses F2-isoprostanes but enhances inflammatory cytokine response in a mouse model of ovalbumin-induced allergic lung inflammation. Free Radic. Biol. Med. 2009, 47:622-628.
62. Song W.L., Paschos G., Fries S., et al. Novel eicosapentaenoic acid-derived F3-isoprostanes as biomarkers of lipid peroxidation. J. Biol. Chem. 2009, 284:23636-23643.
63. Gladine C., Newman J.W., Durand T., et al. Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention. PLoS One 2014, 9:e89393.
64. Jones M.L., Mark P.J., Mori T.A., Keelan J.A., Waddell B.J. Maternal dietary omega-3 fatty acid supplementation reduces placental oxidative stress and increases fetal and placental growth in the rat. Biol. Reprod. 2013, 88:1-8.
65. Kaikkonen J.E., Vilppo T., Asikainen J., Voutilainen S., Kurl S., Salonen J.T. Fatty acids as determinants of in-vivo lipid peroxidation: the EFFGE study in Eastern Finnish hypertensive and non-hypertensive subjects. Ann. Med. 2013, 45:455-464.
66. Kiecolt-Glaser J.K., Epel E.S., Belury M.A., et al. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. Brain Behav. Immun. 2013, 28:16-24.
67. Ramezani M., Nazemian F., Shamsara J., Koohrokhi R., Mohammadpour A.H. Effect of omega-3 fatty acids on plasma level of 8-isoprostane in kidney transplant patients. J. Ren. Nutr 2011, 21:196-199.
68. Hassan A., Ibrahim A., Mbodji K., et al. An α-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-κB in rats with TNBS-induced colitis. J. Nutr. 2010, 140:1714-1721.
69. Mas E., Woodman R.J., Burke V., et al. The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: results from two placebo-controlled interventions. Free Radic. Res. 2010, 44:983-990.
70. Wang H. Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders. Front. Behav. Neurosci. 2014, 8:104.
71. Tsui-Pierchala B.A., Encinas M., Milbrandt J., Johnson E.M. Lipid rafts in neuronal signaling and function. Trends. Neurosci. 2002, 25:412-417.
72. Pfrieger F.W. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 2003, 60:1158-1171.
73. Korade Z., Kenworthy A.K. Lipid rafts, cholesterol, and the brain. Neuropharmacology 2008, 55:1265-1273.
74. Davidson M.H. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol. 2006, 98:27i-33i.
75. Harris W.S. Dietary fish oil and blood lipids. Curr. Opin. Lipidol. 1996, 7:3-7.
76. Illingworth D.R., Schmidt E.B. The influence of dietary n-3 fatty acids on plasma lipids and lipoproteins. Ann. N. Y. Acad. Sci. 1993, 676:60-69.
77. Shapiro J.R., Bibat G., Hiremath G., et al. Bone mass in Rett syndrome: association with clinical parameters and MECP2 mutations. Pediatr. Res. 2010, 68:446-451.
78. Motil K.J., Barrish J.O., Lane J., et al. Vitamin D deficiency is prevalent in girls and women with Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 2011, 53:569-574.
79. Cortelazzo A., De Felice C., Guerranti R., et al. Subclinical inflammatory status in Rett syndrome. Mediat. Inflamm. 2014, 2014:480980.
80. De Felice C., Rossi M., Leoncini S. Inflammatory lung disease in Rett syndrome. Mediat. Inflamm. 2014, 2014:560120.
81. Calder P.C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br. J. Clin. Pharmacol. 2013, 75:645-662.
82. De Palma G., Collins S.M., Bercik P., Verdu E.F. The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both?. J. Physiol. 2014, 592:2989-2997.
83. Chen X., D'Souza R., Hong S.T. The role of gut microbiota in the gut-brain axis: current challenges and perspectives. Protein Cell 2013, 4:403-414.
84. Fetissov S.O., Déchelotte P. The new link between gut-brain axis and neuropsychiatric disorders. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14:477-482.
85. Walsh C.J., Guinane C.M., O'Toole P.W., Cotter P.D. Beneficial modulation of the gut microbiota. FEBS Lett. 2014, (pii: S0014-5793(14)00254-3). 10.1016/j.febslet.2014.03.035.
86. Lee Y.K., Menezes J.S., Umesaki Y., Mazmanian S.K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2011, 108:4615-4622.
87. Garcovich M., Zocco M.A., Roccarina D., Ponziani F.R., Gasbarrini A. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J. Gastroenterol. 2012, 18:6693-6700.
88. Bajaj J. The role of microbiota in hepatic encephalopathy. Gut Microbes 2014, 5:397-403.
89. Moloney R.D., Desbonnet L., Clarke G., Dinan T.G., Cryan J.F. The microbiome: stress, health and disease. Mamm. Genome 2014, 25:49-74.
90. Foster J.A., McVey Neufeld K.A. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013, 36:305-312.
91. Dinan T.G., Cryan J.F. Melancholic microbes: a link between gut microbiota and depression?. Neurogastroenterol. Motil. 2013, 25:713-719.
92. Goyal D.K., Miyan J.A. Neuro-immune abnormalities in autism and their relationship with the environment: a variable insult model for autism. Front. Endocrinol. (Lausanne) 2014, 5:29.
93. Ghosh S., De Coffe D., Brown K., et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS One 2013, 8:e55468.
94. Laparra J.M., Sanz Y. Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol. Res. 2010, 61:219-225.
95. Guy A., Oger C., Heppekausen J., et al. Oxygenated metabolites of n-3 polyunsaturated fatty acids as potential oxidative stress biomarkers: total synthesis of 8-F(3t)-IsoP, 10-F(4t)-NeuroP and [D(4)]-10-F(4t)-NeuroP. Chemistry 2014, 20:6374-6380.
96. Judé S., Bedut S., Roger S., et al. Peroxidation of docosahexaenoic acid is responsible for its effects on I TO and I SS in rat ventricular myocytes. Br. J. Pharmacol. 2003, 139:816-822.